# Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)

> **NCT00352560** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 44 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Irbesartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00352560
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2010-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352560, "Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00352560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*